Sumitomo Mitsui DS Asset Management Company Ltd Has $7.97 Million Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Sumitomo Mitsui DS Asset Management cut its stake in IDEXX by 57.1% in Q4, selling 15,667 shares and leaving 11,778 shares valued at about $7.97 million.
• Company insiders have been active sellers recently — CEO Jonathan Jay Mazelsky and EVP Michael G. Erickson sold large stakes, with insiders offloading 45,957 shares (≈$29.86M) in the past three months and insiders now owning just 0.79%.
• IDEXX beat Q1 estimates (EPS $3.47 vs. $3.41; revenue $1.14B vs. $1.12B), set FY2026 EPS guidance of $14.45–$14.90, and carries a consensus analyst rating of "Moderate Buy" with a $751 target amid mixed individual ratings.

Sumitomo Mitsui DS Asset Management Company Ltd lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 57.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,778 shares of the company's stock after selling 15,667 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in IDEXX Laboratories were worth $7,968,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDXX. EverSource Wealth Advisors LLC raised its holdings in shares of IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company's stock worth $397,000 after buying an additional 15 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company's stock valued at $243,000 after buying an additional 16 shares in the last quarter. CWA Asset Management Group LLC grew its position in IDEXX Laboratories by 3.5% in the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company's stock valued at $344,000 after acquiring an additional 17 shares during the period. Stratos Wealth Partners LTD. grew its position in IDEXX Laboratories by 1.7% in the third quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company's stock valued at $683,000 after acquiring an additional 18 shares during the period. Finally, Cary Street Partners Investment Advisory LLC raised its stake in IDEXX Laboratories by 11.5% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company's stock worth $111,000 after acquiring an additional 18 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IDXX shares. Barclays cut their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Citigroup began coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a "neutral" rating and a $650.00 target price for the company. BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a report on Tuesday, February 3rd. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of IDEXX Laboratories in a research note on Monday, April 27th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $751.00.

Insider Activity at IDEXX Laboratories

In related news, EVP Michael G. Erickson sold 5,371 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares in the company, valued at $7,963,334.34. The trade was a 29.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company's stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at approximately $54,975,125.30. This represents a 21.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 45,957 shares of company stock valued at $29,862,109 in the last three months. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $572.20 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $485.40 and a 52 week high of $769.98. The stock has a market capitalization of $45.14 billion, a PE ratio of 42.14, a PEG ratio of 3.37 and a beta of 1.58. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.90 and a current ratio of 1.12. The stock's fifty day moving average is $585.67 and its 200-day moving average is $649.95.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the company earned $2.91 EPS. The firm's quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 14.64 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.